Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2007-1021594DOI Listing

Publication Analysis

Top Keywords

rare etiology
4
etiology ischemic
4
ischemic colitis
4
colitis amyloid
4
amyloid colitis
4
colitis
2
rare
1
ischemic
1
amyloid
1

Similar Publications

Background: Neonatal sepsis (NNS) is a known cause of morbidity and mortality especially in developing countries. The global resistance scourge may worsen the management outcomes of NNS. This study aims to determine the current profile of bacteriological agents of NNS, their resistance status and associated mortality in our setting.

View Article and Find Full Text PDF

Testicular follicular lymphoma (TFL) is an exceedingly rare lymphoma that typically occurs in young male patients and is now recognized as a distinct diagnostic entity in the International Consensus Classification. TFL shows some clinicopathologic and genetic overlap with pediatric-type follicular lymphoma (PTFL). We report a case of TFL occurring in an otherwise healthy 4-year-old boy who presented with painless scrotal swelling.

View Article and Find Full Text PDF

Background: Limited research exists regarding the genetic profile, clinical characteristics, and outcomes of refractory rickets in children from India.

Methods: Patients with refractory rickets aged ≤ 18 years were enrolled. Data regarding clinical features, etiology, genotype-phenotype correlation, and estimated glomerular filtration rate (eGFR) were recorded.

View Article and Find Full Text PDF

Objective: One of the most severe endocrine side effects of immune checkpoint inhibitors (ICI) is hypophysitis leading to adrenal insufficiency. Recovery is rare, although it has been reported after high-dose glucocorticoid treatment. This is the first randomised study to evaluate whether hormonal recovery differs in patients treated with high-dose glucocorticoids versus glucocorticoid replacement therapy.

View Article and Find Full Text PDF

Background/aims: Rare disease drug development faces unique challenges, such as genotypic and phenotypic heterogeneity within small patient populations and a lack of established outcome measures for conditions without previously successful drug development programs. These challenges complicate the process of selecting the appropriate trial endpoints and conducting clinical trials in rare diseases. In this descriptive study, we examined novel drug approvals for non-oncologic rare diseases by the U.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!